[Federal Register Volume 85, Number 178 (Monday, September 14, 2020)]
[Notices]
[Pages 56633-56634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20160]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-709]


Bulk Manufacturer of Controlled Substances Application: Cambridge 
Isotype Lab

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Cambridge Isotype Lab has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug(s) information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before November 13, 
2020. Such

[[Page 56634]]

persons may also file a written request for a hearing on the 
application on or before November 13, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on July 23, 2020, Cambridge Isotype Lab 50 Frontage 
Road, Andover, Massachusetts 01810-5413, applied to be registered as an 
bulk manufacturer of the following basic class(es) of controlled 
substance(s):

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols................        7370  I
------------------------------------------------------------------------

    The company plans to synthetically bulk manufacture the controlled 
substance Tetrahydrocannabinols to produce analytical standards for 
distribution to its customers. No other activity for this drug code is 
authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-20160 Filed 9-11-20; 8:45 am]
BILLING CODE P